viral genome was cloned [1 ] and serological assays for the detection of antibodies to recombinant expressed Background. Hepatitis E virus ( HEV ) is the causative agent for enteric non-A, non-B hepatitis. Transmission HEV antigens have been developed [2]. Only one type of HEV exists, although several strains including those is via the faecal route but the possibility of transmission by blood has been raised. Data concerning anti-HEV observed from the Mexican and Burmese isolates have been recognized. HEV is largely responsible for waterprevalence among chronic haemodialysis ( HD) patients are few and give conflicting results.
ogical features of HCV and HBV infections in the same control absorbance value were considered to be reactive patients have been previously detailed [22] [23] . The chronic by the criteria of the test. renal failure of the patients was due to chronic glomerulonephritis (n=61), nephroangiosclerosis (n=38 ), polycystic kidney disease (n=29), diabetic nephropathy (n=21 ), Results chronic interstitial nephritis (n=22), and other aetiologies (n=33 ). The history of blood transfusion requirement for There were six of 204 chronic haemodialysis patients each patient was evaluated. No patient admitted a history showing anti-HEV antibody, the anti-HEV prevalence of intravenous drug abuse.
A descriptive analysis of data was made: we calculated in our population was 3% (95% confidence intervals mean±standard deviation and median with respective range 0-6%).
of parametric and non-parametric data respectively.
All these patients did not show very high reactivity; Frequency of categorical variables ( blood transfusions, raised however, no anti-HEV-positive patient had low titres. aminotransferase levels, positivity for viral markers) was In fact, no anti-HEV-positive sample belonged to the assessed.
positive or negative grey-zone (optical density of the sample/cut-off ratio between 0.7 and 1 and between Laboratory assays 0.3 and 0.7 respectively). All anti-HEV-positive patients showed an optical density/cut-off ratio over 1 The patients were screened for HEV markers using a (range 1. showed detectable anti-HBs antibody at the time of Commercially available enzyme immunoassays the study, but they were not included in the calculation ( Abbott Laboratories, North Chicago, IL) were used of previous HBV infection. The prevalence rate of for the detection of HBsAg, IgM anti-HBc, IgG antipersistent and past HBV infection was 39% (79/204) HBs. All the patients were screened for antibodies (95% confidence intervals 31-45%). to HIV (anti-HIV ) by ELISA assay ( Abbott We observed 46/204 patients with anti-HCV antiDiagnostics). Serum aspartate and alanine aminobody, the prevalence of anti-HCV positivity was 22% transferase (AST and ALT ) levels were assayed by (95% confidence intervals 16-28%). spectrophotometry. The upper normal limits in the The descriptive analysis of characteristics of anti-AST and ALT were 46 and 40 U/l respectively. A HEV-positive and anti-HEV-negative patient groups value higher than twice the upper reference level was is shown in Table 1 . arbitrarily considered to be significant.
There were 29/204 (14%) individuals with raised AST and ALT levels. Seven of 204 (3%) had current Anti-HEV IgG detection test (EIA)
increased aminotransferase values, 22/204 (11%) All patients were tested by an enzyme immunoassay showed past elevated aminotransferase concentrations. ( EIA) for specific anti-HEV antibody (Abbott Mean values of increased AST and ALT values were Laboratories, North Chicago, IL). The sample to be 126.5±56.5 and 165.4±90 U/l respectively. No antitested was diluted 15441 in a sample diluent containing HEV positive showed past or current biochemical signs 2% goat anti-human IgG. The diluted sample was of liver disease. incubated for 1 h at 40°C with the HEV-coated beads.
One of six (17%) anti-HEV-positive patients was an The solid phase was coated with two recombinant immigrant from Albania; there was no history of travel antigens expressed in Escherichia coli as fusion proteins in the other (5/6) anti-HEV-positive individuals. There (CKS 8-5 and CKS SG-3) that comprise, respectively, all 123 amino acids of ORF-3 protein and 327 amino Table 1 . Characteristics of anti-HEV-positive and -negative patients acids from the carboxyl terminus of ORF-2 protein of an isolated Burmese strain of HEV. After incubation Patient characteristics Anti-HEV pos.
Anti-HEV neg.
with serum and washing, the bead was further incubated with goat antibody to human IgG (gamma chain were no immigrants in the group of anti-HEV-negative by other authors. A high prevalence of anti-HEV antibody (14%) has been observed among a healthy patients.
population in the Naples area [32] . Moreover, in that report a striking association between HEV and HCV Discussion infection was found. Such an observation is in contrast with our findings. A north-south gradient in HEV prevalence in Europe might be possible. A multicentric We observed a prevalence of anti-HEV antibody of 3% in chronic HD patients attending a single dialysis study regarding HEV prevalence among chronic HD patients attending dialysis units of northern and southunit in northern Italy. Studies concerning HEV epidemiology among chronic HD patients are few and ern Italy is in progress at our Department.
HEV infection, as detected by anti-HEV antibody, give conflicting results. Differences of HEV prevalence in the general population at regional level, the criteria was associated with no risk factor in most patients, and HEV seems to play no role in the development of for inclusion of patients, and the routes of HEV transmission could partially explain the diverse liver disease in HD patients. However, our conclusions must be tempered by the small number of patients results found.
HEV is usually associated with the faeco-oral route, found to be positive for anti-HEV antibody; we made a descriptive analysis of our findings in order to avoid and blood is not considered an important cause of HEV transmission as the virus does not produce a statistical type 2 errors.
In conclusion, this cross-sectional study showed a chronic carrier state. However, experimental transmission of HEV [24] to man showed a transient phase of low prevalence of anti-HEV antibody in our HD patients; we did not find association between HEV and viraemia preceding the onset of clinical symptoms, and prolonged viraemia has been observed in some patients blood-borne viruses; most anti-HEV-positive patients we found are probably the result of local infection by [25, 26 ] . Therefore a theoretical possibility of HEV transmission in endemic areas via a parenteral route HEV. At present hepatitis type E is not a major health problem in industrialized countries; however, there is has been suggested. Such a possibility is supported by the observation that anti-HEV antibody is more fre-an increasing number of travellers to endemic regions for HEV and a high flux of immigrants from these quent in transfusion recipients than in the same number of non-transfused controls [27 ] . However, studies per-areas.
A careful surveillance in the general population is formed in haemophiliacs [28, 29] showed a very low prevalence of HEV infection. Our results suggest that required. A periodical anti-HEV screening in risk groups for viral infections such as HD patients is HD patients, individuals at risk for parenteral exposure, show a low prevalence of HEV infection. recommended. Moreover, we did not find an association between
